



EG-ZERTIFIKAT

(Qualitätssicherung Produktion)



Hiermit wird bescheinigt, dass das Unternehmen

mediDOK Software Entwicklungsgesellschaft mbH

Handschuhsheimer Landstraße 11
69221 Dossenheim
Deutschland

ein Qualitätssicherungssystem für die Herstellung und Endprüfung der Produkte eingeführt hat und anwendet.

Durch ein Audit, dokumentiert in einem Bericht, durchgeführt von DQS Medizinprodukte GmbH, wurde der Nachweis erbracht, dass dieses Qualitätssicherungssystem die Forderungen gemäß

Anhang V der Richtlinie 93/42/EWG des Rates über Medizinprodukte

bezüglich folgender Medizinprodukte erfüllt:

Software für medizinische Anwendung	mediDOK® 2.x DIMEweb x.archiv - powered by mediDOK	Ila Ila Ila
-------------------------------------	--	-------------------

Der Hersteller unterliegt der Überwachung nach Anhang V, Abschnitt 4. Die CE Kennzeichnung mit der Kennnummer der Benannten Stelle (0297) darf an den auf dem Zertifikat gelisteten Produkten angebracht werden. Das Zertifikat beschränkt sich für Produkte der Klasse I(s) (I(s) = Produkte der Klasse I die in sterilem Zustand in Verkehr gebracht werden) ausschließlich auf die Herstellung im Zusammenhang mit der Sterilisation und der Aufrechterhaltung der Sterilität. Das Zertifikat beschränkt sich für Produkte der Klasse I(m) (I(m) = Produkte der Klasse I mit Messfunktion) ausschließlich auf die Herstellung im Zusammenhang mit der Konformität der Produkte mit den messtechnischen Anforderungen.

Zertifikat-Registrier-Nr.	066450 MR5
Zertifikat-ID	170762574
Gültig ab	2020-04-08
Gültig bis	2024-05-26
Frankfurt am Main, den	2020-04-08

DQS Medizinprodukte GmbH

Sigrid Uhlemann
Geschäftsführerin

Dr. Thomas Feldmann
Leiter der Zertifizierungsstelle

August-Schanz-Straße 21, 60433 Frankfurt am Main,
Tel. +49 (0) 69 95427-300, medical.devices@dqs-med.de

Die DQS Medizinprodukte GmbH ist Benannte Stelle gemäß der Richtlinie 93/42/EWG des Rates über Medizinprodukte mit der Kennnummer 0297.





DQS Medizinprodukte GmbH | August-Schanz-Str. 21 | 60433 Frankfurt am Main

mediDOK Software Entwicklungsgesellschaft mbH
Handschuhsheimer Landstraße 11
69221 Dossenheim
Germany

2024-06-04

Notified Body Confirmation Letter

Reference: 170762574

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical device

This letter confirms that, DQS Medizinprodukte GmbH, a Notified Body designated against Regulation (EU) 2017/745 (MDR) and identified by the number 0297 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

mediDOK Software Entwicklungsgesellschaft mbH

Handschuhsheimer Landstraße 11

69221 Dossenheim

Germany

SRN: DE-MF-000006227

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables listed below: Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which DQS Medizinprodukte GmbH is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but DQS Medizinprodukte GmbH has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

DQS Medizinprodukte GmbH
Managing Director:
Sigrid Uhlemann

August-Schanz-Str. 21
60433 Frankfurt am Main
Germany

Phone +49 69 95427-300
Fax +49 69 95427-388
info-med@dqs.de
www.dqsglobal.com

Registered in Frankfurt a.M.
AG HRB 83350
VAT: DE 260 263 917





In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry, or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body,

A handwritten signature in black ink, appearing to read 'T. Unverzagt'.

Tim Unverzagt

Regulatory Affairs Manager



Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name and Basic UDI-DI (as proposed by the manufacturer within the application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
mediDOK® 2.x (original product)	Class IIa	Software für medizinische Anwendung –	<i>MDD-Certificate References:</i>
DIMEweb (trade variant of mediDOK® 2.x)	Class IIa	mediDOK® 2.x, class IIa	066450 MR5 170762574
x.archiv – powered by mediDOK (trade variant of mediDOK® 2.x)	Class IIa	DIMEweb, class IIa x.archiv – powered by mediDOK, class IIa	<i>NB Identification:</i> 0297 (DQS Medizinprodukte GmbH)
Basic UDI-DI: 426067425MDRN			

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name and Basic UDI-DI (as proposed by the manufacturer within the application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	N/A	N/A	N/A

Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2024-06-04	170762574	Initial issue